Oxazine Derivatives Inhibit BACE-1 to Reduce Amyloid Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Alzheimer's Disease are inadequate in addressing the increased generation and deposition of amyloid peptides, leading to neuronal loss and cognitive decline, as existing treatments fail to effectively inhibit the key enzyme BACE-1 responsible for amyloid peptide formation.
Innovation Solution
Development of novel oxazine derivatives with BACE inhibitory activity, specifically designed to target and inhibit the enzyme BACE-1, thereby reducing amyloid peptide generation and deposition in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic strategies are used for Alzheimer's Disease, then treatment is provided, but they fail to effectively inhibit BACE-1 and address amyloid peptide generation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of BACE-1 inhibitors through various substitutions at positions R1-R6, including different alkyl groups, halogens, and heteroatoms, to optimize inhibitory activity and selectivity for the enzyme while improving therapeutic effectiveness
Solution Approach 2:
The invention uses composite molecular structures combining oxazine core with diverse substituent groups (aryl, heteroaryl, cycloalkyl, alkyl chains) to create compounds with enhanced BACE-1 inhibition capability that overcomes the limitations of existing monofunctional therapeutic approaches
2Object-affected harmful factors
If amyloid peptide generation is not inhibited, then existing treatments are simple, but neuronal loss and cognitive decline progress
Solution Approach 1:
The patent implements preliminary action by designing compounds that proactively inhibit BACE-1 before amyloid peptides can be generated and deposited, preventing the harmful cascade leading to neuronal loss and cognitive decline rather than treating symptoms after they occur
Solution Approach 2:
The oxazine derivative compounds serve as intermediary substances that mediate between the administration system and the BACE-1 enzyme, providing a bridge that delivers targeted inhibition while allowing for optimization of pharmacokinetic properties through structural modifications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oxazine derivatives effectively inhibit BACE-1, potentially slowing down the progression of Alzheimer's Disease by reducing amyloid peptide formation and deposition, thereby mitigating neuronal loss and cognitive decline.
Implementation Method 1
BACE-1, also known as Asp2 or Memapsin 2, is a transmembrane aspartic protease highly expressed in neurons. It co-localizes with its substrate APP in Golgi and endocytic compartments
Data Source
AI summary
The invention relates to novel heterocyclic compounds of the formulain which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.